InvestorsHub Logo
Followers 0
Posts 1587
Boards Moderated 0
Alias Born 08/09/2015

Re: JRIII post# 179965

Thursday, 06/28/2018 8:28:25 AM

Thursday, June 28, 2018 8:28:25 AM

Post# of 704669
I think the only endpoint that matters in the end is OS, even in the approval process.

The most revealing recent number is 24% of blended patients survived 36 mos with a K-M extrapolated mOS of 88 mos. If this number creeps close to 30% for DCVax-L treated patients in the 2018 refresh, that is the big one.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News